Cell-free DNA as a new, minimally invasive and sensitive biomarker for early detection of allograft rejection after heart transplantation

Cell-free DNA as a new, minimally invasive and sensitive biomarker for early detection of allograft rejection after heart transplantation - cfDNA for detection of heart transplant rejection

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON45738

Enrollment

Registered

2017-09-08

Start date

2017-09-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiac surgery heart disease

Interventions

cell-free

heart transplantion

rejection

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Adult (*18 years) heart transplant patients

Exclusion criteria

Exclusion criteria: No written informed consent

Design outcomes

Primary

Measure	Time frame
Sensitivity: percentage of patients positive for rejection according to the golden standard EMB that are also positive according to the ddPCR technique.	—

Secondary

Measure	Time frame
Not applicable.	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)